NASDAQ · Biotechnology · USD
IN8bio, Inc. (INAB) Stock Analysis
IN8bio, Inc. (INAB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
INAB Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.16
- Previous Close
- $1.14
- Day's Range
- 1.05–1.16
- 52-Week Range
- 0.88–2.73
- Volume
- 32.21K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.30
Valuation
- Market Cap
- $10.75M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.62
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$19.44M
- Shares Outstanding
- 9.86M
- 1-Year Return
- −47.85%
Dividend and dates
- Avg Volume
- 53.71K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, INAB closed at $1.09, −47.85% over 1 year.
IN8bio, Inc. (INAB) has a market capitalization of $10.75M.
In fiscal 2025, INAB reported revenue of $0.00.
INAB Stock Return by Calendar Year
IN8bio, Inc. (INAB) return since Jul 2021: what $10,000 became
- 1 year
- $10,000 $5,215
- −47.85%
- 5 years
- $10,000 $55
- −99.45%
- Since Jul 2021
- $10,000 $36
- −99.64%
If you had invested $10,000 in IN8bio, Inc. (INAB) at the close on July 30, 2021, the earliest close on record here, it would have been worth $36 at the close on October 21, 2026: −99.64% in total, −65.86% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −53.42% |
| 2025 | −69.65% |
| 2024 | −81.38% |
| 2023 | −40.26% |
| 2022 | −47.38% |
| 2021 (partial year) | −56.10% |
As of October 21, 2026.
INAB Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$19.44M | — |
| 2024 | $0.00 | −$30.44M | — |
| 2023 | $0.00 | −$30.01M | — |
| 2022 | $0.00 | −$28.52M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$19.86M | −$19.44M | — |
| 2024 | $0.00 | — | −$29.60M | −$30.44M | — |
| 2023 | $0.00 | — | −$30.01M | −$30.01M | — |
| 2022 | $0.00 | — | −$28.52M | −$28.52M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
YahooIN8bio to Present at Sidoti Small-Cap Virtual Conference
YahooIN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
YahooIN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
YahooIN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B